Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunoglobulin domains

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Immunoglobulin domains. Displaying page 1 of 1.
    EudraCT Number: 2018-003171-35 Sponsor Protocol Number: IgPro20_3007 Start Date*: 2019-09-24
    Sponsor Name:CSL Behring LLC
    Full Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001598-25 Sponsor Protocol Number: IG1002 Start Date*: 2011-10-25
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra...
    Medical condition: Mild to Moderate Alzheimer's Disease patients.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004476-35 Sponsor Protocol Number: CCFZ533B2201 Start Date*: 2019-08-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations o...
    Medical condition: Sjögren syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) FR (Completed) DE (Completed) SE (Completed) AT (Completed) SI (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000620-34 Sponsor Protocol Number: Imatinib-MS Start Date*: 2018-04-24
    Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet
    Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
    Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003141-11 Sponsor Protocol Number: NBI-827104-CSWS2010 Start Date*: 2021-09-03
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with E...
    Medical condition: Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002234-14 Sponsor Protocol Number: OR2805-101 Start Date*: 2023-06-07
    Sponsor Name:OncoResponse, Inc.
    Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
    Medical condition: Solid tumor cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000867-21 Sponsor Protocol Number: NGAM-13 Start Date*: 2021-08-16
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
    Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004827-22 Sponsor Protocol Number: BM41-VD3 Start Date*: 2017-07-25
    Sponsor Name:Academic Medical Center
    Full Title: A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to...
    Medical condition: moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005443-14 Sponsor Protocol Number: NGAM-08 Start Date*: 2017-04-28
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radic...
    Medical condition: Chronic Inflammatory Demyelinating Poly(radiculo)-neuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-001023-38 Sponsor Protocol Number: bb2121-MM-003 Start Date*: 2019-05-13
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (...
    Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Completed) DE (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002063-60 Sponsor Protocol Number: PRN1008-018(EFC17093) Start Date*: 2020-11-12
    Sponsor Name:Principia Biopharma, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults...
    Medical condition: Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) NO (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000571-20 Sponsor Protocol Number: D9180C00002 Start Date*: 2020-10-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Dise...
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) HU (Completed) NL (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-000391-28 Sponsor Protocol Number: 951404713 Start Date*: 2017-09-20
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN)
    Medical condition: LUPUS NEPHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003838-88 Sponsor Protocol Number: M13-494 Start Date*: 2018-09-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple ...
    Medical condition: R/R Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Trial now transitioned) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Restarted) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004518-24 Sponsor Protocol Number: I4V-MC-JAHV Start Date*: 2019-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004471-31 Sponsor Protocol Number: I4V-MC-JAHX Start Date*: 2019-06-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA)
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002012-23 Sponsor Protocol Number: SL79.22 Start Date*: Information not available in EudraCT
    Sponsor Name:STALLERGENES
    Full Title: A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-in...
    Medical condition: Birch Pollen-induced Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000720-17 Sponsor Protocol Number: MOM-M281-006 Start Date*: 2020-01-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension
    Medical condition: Adults with Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10002285 Anemia hemolytic autoimmune (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Temporarily Halted) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 20:24:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA